Cargando…

ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did

Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures...

Descripción completa

Detalles Bibliográficos
Autores principales: Demers, Elizabeth, Hendrikse, Jurian, Joos, Philip, Lev, Baruch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251456/
https://www.ncbi.nlm.nih.gov/pubmed/34230747
http://dx.doi.org/10.1111/jbfa.12523
_version_ 1783717097300295680
author Demers, Elizabeth
Hendrikse, Jurian
Joos, Philip
Lev, Baruch
author_facet Demers, Elizabeth
Hendrikse, Jurian
Joos, Philip
Lev, Baruch
author_sort Demers, Elizabeth
collection PubMed
description Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures of performance, financial position and intangibles investments have been controlled for, ESG offers no such positive explanatory power for returns during the COVID crisis. Specifically, ESG is insignificant in fully specified returns regressions for each of the Q1 2020 COVID market crisis period and for the full COVID year of 2020. By contrast, a measure of the firm's stock of investments in internally generated intangible assets is an economically and statistically significant positive determinant of returns during each of the Q1 market implosion and full 2020 COVID year periods. Our results are robust to alternative measures of returns, as well as for using Refinitiv, Refinitiv II and MSCI data to capture ESG performance. We conclude that ESG did not immunize stocks during the COVID‐19 crisis, but those investments in intangible assets did.
format Online
Article
Text
id pubmed-8251456
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82514562021-07-02 ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did Demers, Elizabeth Hendrikse, Jurian Joos, Philip Lev, Baruch J Bus Finance Account Articles Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures of performance, financial position and intangibles investments have been controlled for, ESG offers no such positive explanatory power for returns during the COVID crisis. Specifically, ESG is insignificant in fully specified returns regressions for each of the Q1 2020 COVID market crisis period and for the full COVID year of 2020. By contrast, a measure of the firm's stock of investments in internally generated intangible assets is an economically and statistically significant positive determinant of returns during each of the Q1 market implosion and full 2020 COVID year periods. Our results are robust to alternative measures of returns, as well as for using Refinitiv, Refinitiv II and MSCI data to capture ESG performance. We conclude that ESG did not immunize stocks during the COVID‐19 crisis, but those investments in intangible assets did. John Wiley and Sons Inc. 2021-04-08 2021 /pmc/articles/PMC8251456/ /pubmed/34230747 http://dx.doi.org/10.1111/jbfa.12523 Text en © 2021 The Authors. Journal of Business Finance & Accounting published by John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Demers, Elizabeth
Hendrikse, Jurian
Joos, Philip
Lev, Baruch
ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title_full ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title_fullStr ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title_full_unstemmed ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title_short ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
title_sort esg did not immunize stocks during the covid‐19 crisis, but investments in intangible assets did
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251456/
https://www.ncbi.nlm.nih.gov/pubmed/34230747
http://dx.doi.org/10.1111/jbfa.12523
work_keys_str_mv AT demerselizabeth esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid
AT hendriksejurian esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid
AT joosphilip esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid
AT levbaruch esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid